A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma
Abstract Background This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CXD101 in patients with relapsed / refractory lymphoma or advanced solid organ cancers and...
Main Authors: | Stephen W. Booth, Toby A. Eyre, John Whittaker, Leticia Campo, Lai Mun Wang, Elizabeth Soilleux, Daniel Royston, Gabrielle Rees, Murali Kesavan, Catherine Hildyard, Farasat Kazmi, Nick La Thangue, David Kerr, Mark R. Middleton, Graham P. Collins |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-07-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08595-w |
Similar Items
-
Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
by: Giorgio Milazzo, et al.
Published: (2020-05-01) -
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
by: Maria Cosenza, et al.
Published: (2018-08-01) -
Improving histone deacetylase inhibition therapy through isoform selectivity and targeted delivery
by: Sodji, Quaovi Hemeka
Published: (2015) -
Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
by: Delcuve Geneviève P, et al.
Published: (2012-03-01) -
HDAC3 and HDAC8 are required for cilia assembly and elongation
by: Seon-ah Park, et al.
Published: (2019-08-01)